SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514. Read More » July 29, 2024
SERDA Therapeutics completes a € 2 Million funding round to develop an innovative enzymatic wound debridement product Read More » June 3, 2024
SERDA therapeutics submits IND for its lead product, an innovative wound debridement agent. Read More » February 17, 2023
